Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for fatigue in relapsing-remitting multiple sclerosis
IRCT20240118060725N1Phase 3Completed
- Sponsor
- Qazvin University of Medical Sciences
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple sclerosis (MS) comparing Memantine with Placebo (2 arms). Primary endpoints: Physical aspect of Modified Fatigue Impact Scale, Cognitive aspect of Modified Fatigue Impact Scale and 2 more. Started Mar 2024; status: completed.
02
Drugs
memantine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20240118060725N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240118060725N1.